Recognizing excellence and milestones in the journey.
Building global platforms for researchers to collaborate on pharmaceutical research, including "Massive Online Open Research" (MOOR) initiatives for COVID-19.
Multiple scientific papers have been published in international peer-reviewed academic journals
OSPF has commenced a multicentric phase 2b clinical trial for an adjunct therapy for tuberculosis, reaching this stage nearly a decade faster and for roughly less than 1% the cost as compared to conventional big pharma approaches. The initial 200+ patients have been enrolled, with all centers operative. The Government of India’s Chennai-based National Institute for Research in Tuberculosis (NIRT) is the primary sponsor and OSPF is the secondary sponsor. The trial has been prospectively registered on the government of India clinical trials web site, where the protocol can be viewed – see www.ctri.nic.in, CTRI No. 011176. An article on the trial has been published in the British Medical Journal - see article. We have committed to making the IP from this trial open and placed in the public domain, and also to making data from the trial open. Generally, we will imbue clinical trials with open source methodologies to the maximum extent feasible; gradually at first and increasing over time.
A series of workshops connecting women scientists through virtual labs and whittling down potential molecules that could eventually be turned into drugs to fight diseases, such as tuberculosis. Reported by BBC News
